200 related articles for article (PubMed ID: 37419875)
1. Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
Kouno T; Shibata S; Shigematsu M; Hyun J; Kim TG; Matsuo H; Wolf M
Nat Commun; 2023 Jul; 14(1):4037. PubMed ID: 37419875
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
3. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
5. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
Iwatani Y; Chan DS; Liu L; Yoshii H; Shibata J; Yamamoto N; Levin JG; Gronenborn AM; Sugiura W
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19539-44. PubMed ID: 19887642
[TBL] [Abstract][Full Text] [Related]
8. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
Chesarino NM; Emerman M
J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
[TBL] [Abstract][Full Text] [Related]
11. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
Dang Y; Siew LM; Zheng YH
J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
[TBL] [Abstract][Full Text] [Related]
13. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
Martin KL; Johnson M; D'Aquila RT
J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
[TBL] [Abstract][Full Text] [Related]
15. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
[TBL] [Abstract][Full Text] [Related]
16. Aromatic disulfides as potential inhibitors against interaction between deaminase APOBEC3G and HIV infectivity factor.
Yan X; Chen C; Wang C; Lan W; Wang J; Cao C
Acta Biochim Biophys Sin (Shanghai); 2022 May; 54(5):725-735. PubMed ID: 35920198
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G: a double agent in defense.
Smith HC
Trends Biochem Sci; 2011 May; 36(5):239-44. PubMed ID: 21239176
[TBL] [Abstract][Full Text] [Related]
18. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
Green LA; Liu Y; He JJ
J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
[TBL] [Abstract][Full Text] [Related]
20. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]